Marrone Bio Innovations Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Marrone Bio Innovations Inc (MBII) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Marrone Bio Innovations Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 44M vs 118,014M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.0% annualized vs trailing 12 months), vs accelerating (+37.9%) for its tracked peer group.
- Growth: Marrone Bio Innovations Inc generated 0.5% revenue growth year over year in Q1 2022, vs 23.0% for its competitors combined.
- Profitability: Its -68.5% net margin compares with 9.0% for the peer group.
- Peer revenue share: Marrone Bio Innovations Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.46M compares with $0.62M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MBII Sales vs. its Competitors, Q1 2022
Marrone Bio Innovations Inc reported revenue growth of 0.53 % year on year in Q1 2022, below its competitors' combined revenue growth of 22.98 %.
With a net margin of -68.45 %, Marrone Bio Innovations Inc reported lower profitability than its competitors (8.95 %).
Marrone Bio Innovations Inc generated 0.03 % of the combined sales of its peer group, up from 0.03 % a year earlier.
API endpoints for this dataset
Marrone Bio Innovations Inc vs. its Competitors, Q1 2022
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Marrone Bio Innovations Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Marrone Bio Innovations Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Marrone Bio Innovations Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Marrone Bio Innovations Inc's competitor groups requires a Commercial License.
For context: the Agricultural Production industry grew revenue 7.4% year over year, combined, vs 0.5% for Marrone Bio Innovations Inc. Marrone Bio Innovations Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Marrone Bio Innovations Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Marrone Bio Innovations Inc | No | Yes | Yes | Yes |
| Competitors combined (17) | ||||
| High-Confidence Competitors (1) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MBII Stock Performance relative to its Competitors
MBII Stock Performance relative to High-Confidence Competitors
MBII Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | I minerals Inc | 282.9% | Outperformed |
| 2 | Cf Industries Holdings inc | 282.9% | Outperformed |
| 3 | Dow Inc | 282.9% | Outperformed |
| 4 | Dupont De Nemours Inc | 282.9% | Outperformed |
| 5 | Intrepid Potash inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Marrone Bio Innovations Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Marrone Bio Innovations Inc's Comment on Competition and Industry Peers
For pest management products, performance and value are critical competitive factors. To compete against manufacturers of conventional chemical pesticides and genetically modified crops, we need to demonstrate the advantages of our products over these more established pest management products. Many large agrichemical companies are developing, and have introduced, new conventional chemical pesticides and genetically modified products that they believe are safer and more environmentally friendly than older conventional chemical products.
The pest management market is very competitive and is dominated by multinational
chemical and life sciences companies such as Arysta, BASF, Bayer, Dow Agrosciences
and DuPont (potentially merging to become DowDuPont), FMC, Monsanto (being acquired
by Bayer), Sumitomo Chemical and Syngenta (being acquired by ChemChina). Universities,
research institutes and government agencies may also conduct research, seek
patent protection and, through collaborations, develop competitive pest management
products. Other companies, including bio-specialized biopesticide businesses
such as AgraQuest (now a part of Bayer), Certis USA (now a part of Mitsui),
Novozymes (in a joint venture with Monsanto) and Valent Biosciences (now a part
of Sumitomo) may prove to be significant competitors in the bio-based pest management
and plant health market. In addition, we could face competition in the future
from new, well-financed start-up companies such as AgBiome and Indigo.
In many instances, agrichemical companies have substantially greater financial,
technical, development, distribution and sales and marketing resources than
we do. Moreover, these companies may have greater name recognition than we do
and may offer discounts as a competitive tactic. There can be no assurance that
our competitors will not succeed in developing pest management products that
are more effective or less expensive than ours or that would render our products
obsolete or less competitive. Our success will depend in large part on our ability
to maintain a competitive position with our technologies and products.
Publicly Traded Peers of Marrone Bio Innovations Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Marrone Bio Innovations Inc |
145.46 | 44.37 |
 Honeywell International Inc |
71,325.24 | 30,716.00 |
 Dow Inc |
24,113.31 | 40,494.00 |
 Dupont De Nemours Inc |
20,899.97 | 3,526.00 |
 Cf Industries Holdings inc |
19,225.19 | 7,739.00 |
 Cerevel Therapeutics Holdings Inc |
8,165.22 | 0.00 |
| SUBTOTAL | 164,615.41 | 118,058.19 |
Sign in to see all competitors of Marrone Bio Innovations Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Marrone Bio Innovations Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Marrone Bio Innovations Inc's Competitors Named by the Company
Competitive relationships identified from Marrone Bio Innovations Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Phillips McDougal | Company report | 85% |
| Jet-Oxide | Company report | 85% |
| DunhamTrimmer | Company report | 85% |
| MarketandMarkets | Company report | 85% |
| Jet-Ag | Company report | 85% |
| Fmc Corporation | Company report | 85% |
| China Green Agriculture Inc | Company report | 85% |
| Arcadia Biosciences Inc | Company report | 85% |
| Dupont De Nemours Inc | Company report | 85% |
| American Vanguard Corporation | Company report | 85% |
| Mosaic Co | Company report | 85% |
Company report basis, confidence, active dates and source counts for Marrone Bio Innovations Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Marrone Bio Innovations Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Honeywell International Inc | Building Automation 40.45 % |
| Dow Inc | Operating Segment Total 98.39 % |
| Dupont De Nemours Inc | Diversified Industrials 52.87 % |
| Cf Industries Holdings inc | UAN 34.35 % |
| Eastman Chemical Co | Additives And Functional Products 32.87 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Marrone Bio Innovations Inc .
Marrone Bio Innovations Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Marrone Bio Innovations Inc | 145 | 457,412 | -215,351 |
| Honeywell International Inc | 71,325 | 304,119 | 69,525 |
| Dow Inc | 24,113 | 1,170,347 | -38,728 |
| Dupont De Nemours Inc | 20,900 | 235,067 | 20,933 |
| Cf Industries Holdings inc | 19,225 | 2,668,621 | 862,069 |
| Cerevel Therapeutics Holdings Inc | 8,165 | 0 | -1,771,031 |
| PEERS TOTAL | 164,470 | 624,848 | 20,099 |
Sign in to see all peers for Marrone Bio Innovations Inc .
Marrone Bio Innovations Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Dow Inc | U.S.& Canada 40.37 % |
| Dupont De Nemours Inc | Asia Pacific 23.77 % |
| Cf Industries Holdings inc | North America 78.28 % |
| Mosaic Co | Brazil 38.39 % |
| Fmc Corporation | Asia 86.21 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Marrone Bio Innovations Inc .
Marrone Bio Innovations Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Agricultural Production industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (67 companies). See the full Agricultural Production industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.60 % | 15.49 % (avg) | -14.9 pp |
| Operating Margin | -0.43 % | industry median | +38.6 pp |
| EBITDA Margin | 26.50 % | 2.62 % (avg) | +23.9 pp |
| Capital Intensity (Capex / Revenue) | 2.64 % | 4.99 % (avg) | -2.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Marrone Bio Innovations Inc's Valuation vs Competitive Position
Valuation multiples vs the Agricultural Production industry average (67 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Agricultural Production industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 18.5x | - |
| EV / EBITDA | - | 10.0x | - |
| P/B | 4.7x | 1.9x | +2.7x |
| Return on Equity | -0.71 % | industry aggregate | -13.64 % |
| Return on Invested Capital | -0.28 % | -2.60 % (avg) | 2.32 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Marrone Bio Innovations Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenue Growth | 378.10 % | 36.95 % | 16.81 % | 38.42 % | 30.64 % | 15.47 % |
| Operating Margin | -402.58 % | -126.58 % | -91.91 % | -95.27 % | -44.81 % | -34.76 % |
| Return on Invested Capital | -69.21 % | - | -34.87 % | -48.13 % | -21.27 % | -17.78 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Marrone Bio Innovations Inc's Strategic Group Map
Marrone Bio Innovations Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Marrone Bio Innovations Inc's trailing-12-month revenue growth of 11.6% and operating margin of -0.4% compares with an average of 9.1% growth and 1.6% margin across its 8 closest peers by combined growth, margin and ROIC -- Marrone Bio Innovations Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Marrone Bio Innovations Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.64 % vs industry average 4.99 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Marrone Bio Innovations Inc's dedicated Suppliers and Customers pages, not here.
Marrone Bio Innovations Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Marrone Bio Innovations Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Marrone Bio Innovations Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 38.6 points above the industry median.
Weaknesses
- Return on equity 13.6 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Marrone Bio Innovations Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Marrone Bio Innovations Inc | 0.44 | 1.09 | 0.94 |
| Honeywell International Inc | 0.47 | 1.24 | 1.69 |
| Dow Inc | 0.40 | 1.87 | 1.01 |
| Dupont De Nemours Inc | 0.59 | 2.47 | 0.23 |
| Cf Industries Holdings inc | 0.17 | 3.34 | 0.39 |
| Cerevel Therapeutics Holdings Inc | 3.33 | 10.31 | 0.91 |
Sign in to see all peers for Marrone Bio Innovations Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Marrone Bio Innovations Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Marrone Bio Innovations Inc | Q1 2022 | +0.5 % | - |
| Honeywell International Inc | Q3 2026 | -52.0 % | -64.3 % |
| Dow Inc | Q3 2026 | +11.5 % | - |
| Dupont De Nemours Inc | Q3 2026 | -38.2 % | - |
| Cf Industries Holdings inc | Q2 2026 | +17.6 % | +76.6 % |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | - |
| PEERS TOTAL | -12.6 % | -71.7 % |
Sign in to see all peers for Marrone Bio Innovations Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Marrone Bio Innovations Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Marrone Bio Innovations Inc | Q1 2022 | +20.2 % | +66.4 % |
| Honeywell International Inc | Q3 2026 | -5.7 % | - |
| Dow Inc | Q3 2026 | +3.9 % | +98.0 % |
| Dupont De Nemours Inc | Q3 2026 | +1.9 % | -4.1 % |
| Cf Industries Holdings inc | Q2 2026 | -5.1 % | +10.6 % |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | -19.3 % |
Sign in to see all peers for Marrone Bio Innovations Inc .
Marrone Bio Innovations Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Marrone Bio Innovations Inc | - | - | - |
| Honeywell International Inc | 10.10% | 15.11% | 39.45% |
| Dow Inc | - | - | - |
| Dupont De Nemours Inc | 1.48% | 1.58% | 2.25% |
| Cf Industries Holdings inc | 17.24% | 15.64% | 30.63% |
| Cerevel Therapeutics Holdings Inc | - | - | - |
Sign in to see all peers for Marrone Bio Innovations Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Marrone Bio Innovations Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Marrone Bio Innovations Inc | - | 3.28 |
| Honeywell International Inc | 10.63 | 2.32 |
| Dow Inc | - | 0.60 |
| Dupont De Nemours Inc | 75.46 | 5.93 |
| Cf Industries Holdings inc | 9.33 | 2.48 |
| Cerevel Therapeutics Holdings Inc | - | - |
| PEERS AVERAGE | 43.60 | 1.39 |
Sign in to see all peers for Marrone Bio Innovations Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.